Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Stoke Therapeutics, Inc.

STOK ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$28.93

▲ +3.65%

Market Cap $1.87B · Vol 229.56K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.87B

Small Cap

Div Yield

N/A

EPS Growth

-2,936.91%

YoY

RSI (14)

25.00

Momentum

Beta

1.26

vs Market

52W High

$40.18

30.54% below

52W Low

$20.32

37.35% above

Volume

229.56K

Avg 249.09K

P/B

5.31

Price-to-book

ROE

N/A

Return on equity

Free Float

96.30%

Public shares

Shariah Compliance8 STANDARDS

✗ Stoke Therapeutics, Inc. (STOK) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does STOK pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.40%

-9.96%

-4.40%

-11.99%

YTD

-8.85%

+27.22%

+480.92%

+14.62%

Financials & Valuation

TTM · Annual

Total Revenue	$184.42M
Net Income	$-6,885,000.00
Revenue Growth (YoY)	-32.51%
Gross Margin	100.00%
Operating Margin	-11.16%
Net Profit Margin	-3.73%
ROE	N/A
ROA · ROIC	-2.00% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	10.19
P/B	5.31
P/FCF	41.85
EPS Growth	-2,936.91%
Outstanding Shares	64.53M

Technical Indicators

50-Day SMA	$30.61
200-Day SMA	$31.94
RSI (14)	25.00
Beta	1.26
52-Week High	$40.18
52-Week Low	$20.32

Volume Today	229.56K
Avg Daily Volume (30D)	249.09K
Relative Volume	0.92x
Volatility (10D)	34.94
Volatility (30D)	37.13
Free Float	96.30%

Analyst Consensus

BUY

Current Price $28.93

Mean Target $47.00

52W Low$20.32 52W High$40.18

Current

Target

$20.32 $40.18

Current Analyst target

+62.46% upside potential · 14 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00JPCBPH8

ISINUS86150R1077

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.23% ONC BeOne Medicines AG +1.55% 068270.KS Celltrion, Inc. +1.75% ABVX Abivax SA +4.66% ABVX.PA Abivax SA +3.59%

Company Profile

Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.